2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma, B-Cell
19
Lymphoma, Large B-Cell, Diffuse
18
Recurrence
13
Lymphoma, Non-Hodgkin
13
Multiple Myeloma
12
Burkitt Lymphoma
11
Lymphoma, Mantle-Cell
8
Lymphoma
8
Leukemia, Myeloid, Acute
8
Carcinoma, Hepatocellular
7
Pancreatic Neoplasms
6
Neoplasms
6
Lymphoma, Follicular
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Leukemia
5
Glioma
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Leukemia, B-Cell
4
Hematologic Neoplasms
4
Neoplasm, Residual
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Esophageal Neoplasms
3
Breast Neoplasms
3
Simpson-Golabi-Behmel syndrome
2
Sarcoma, Synovial
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Interventions
Gemcitabine
15
130-nm albumin-bound paclitaxel
10
Albumin-Bound Paclitaxel
7
Oxaliplatin
5
Paclitaxel
4
Leucovorin
4
Fluorouracil
4
Carboplatin
4
Cisplatin
3
Cetuximab
3
Bevacizumab
3
pembrolizumab
2
napabucasin
2
Pemetrexed
2
PEGPH20
2
MK-4721
2
Irinotecan
2
tremelimumab
1
selinexor
1
relacorilant
1
ponatinib
1
neratinib
1
irinotecan sucrosofate
1
folfirinox
1
ensituximab
1
durvalumab
1
contrast agent BR1
1
cobimetinib
1
ceritinib
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Pancreatic Ductal
×
Immunotherapy, Adoptive
×
Clear all
NCT07153289
2025-09-03
ResCPa
University Hospital Tuebingen
Phase 1/2
Not yet recruiting
38 enrolled